This list includes the latest research on the science, business, & regulation of prescription drugs & vaccines posted to SSRN in 2025.

• Legal Underpinnings of the Great Vaccine Debate of 2025 by James G. Hodge (Arizona State University)
  
• The Paradox between Vaccination Rate and COVID-19 Mortality: Numerous Socioeconomic and Environmental Elements that Promote Spread by Mario Coccia (National Research Council of Italy)
  
• From Human Rights to the Pandemic Agreement and Beyond: Reframing Vaccines Access Through a Framework of ‘States Capabilities’ by Pramiti Parwani (University of Amsterdam)
  
• COVID-19 Vaccine Effectiveness against Medically Attended Symptomatic SARS-CoV-2 Infection among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network by Charlotte Lanièce Delaunay (Epiconcept), Nuno Verdasca (National Health Institute Doutor Ricardo Jorge), Susana Monge (Carlos III Institute of Health), Lisa Domegan (Health Protection Surveillance Centre), Noémie Sève (Sorbonne University), Silke Buda (Robert Koch Institute), Adam Meijer (National Institute for Public Health and the Environment), Héloïse Lucaccioni (Epiconcept), Miriam López Torrijos (Subdirección General de Epidemiología y Vigilancia de la Salud), Adele McKenna (Health Service Executive), Vincent Enouf (University of Paris-Saclay), Ralf Dürrwald (Robert Koch Institute), Eline In‘t Velt (National Institute for Public Health and the Environment), Mª Ángel Valcárcel de Laiglesia (Murcia Regional Health Council), Charlene Bennett (University College Dublin), Shirley Masse (University of Corsica), Annika Erdwiens (Robert Koch Institute), Mariëtte Hooiveld (Netherlands Institute for Health Services Research), Ivan Mlinarić (Croatian Institute of Public Health), Gergő Túri (Semmelweis University), Ana Paula Rodrigues (National Health Institute Doutor Ricardo Jorge), Iván Martínez-Baz (Universidad Pública de Navarra), Mihaela Lazar (Cantacuzino National Military Medical Institute for Research and Development), Neus Latorre-Margalef (Public Health Agency of Sweden), Vítor Borges (National Health Institute Doutor Ricardo Jorge), Marlena Kaczmarek (European Centre for Disease Prevention and Control), Sabrina Bacci (European Centre for Disease Prevention and Control), & Esther Kissling (Epiconcept)
  
• Cervical Cancer in the HPV-Vaccination Cohort in the Netherlands by Luc van Lonkhuijzen (University of Amsterdam), Constantijne Mom (University of Amsterdam), & Maaike van der Aa (Netherlands Comprehensive Cancer Organisation)
  
• Policy Strategies for Inclusion of Pregnant and Lactating People in Vaccine Research by Danielle Serota (Washington University in St-Louis), Chelsea Crooks (Cornell University), Emma McGinty (Cornell University), Sallie Permar (Cornell University), & Laura Riley (Cornell University)
  
• A New Framework for Drug Pricing Law and Policy by Rachel Sachs (Washington University in Saint Louis)
  
• Pharmaceutical Drug Regulation and Mortality: Evidence from E-cigarettes by Michael Pesko (University of Missouri), Christian Saenz (Georgia State University)
  
• Reframing Drug Price Regulation in the U.S.: Using Tools that Work Date by Deborah Williams (Health Policy Insights LLC), Steven Zima (CIGNA), & Brian Miller (Johns Hopkins University)
  
• Procurement Institutions and Essential Drug Supply in Low and Middle-Income Countries by Lucy Xiaolu Wang (University of Massachusetts Amherst) & Nahim Bin Zahur (Queen’s University)
  
• Towards FDA-USPTO Cooperation by John (Jay) R. Thomas (Georgetown University Law Center)
  

To read more research on the science, business, & regulation of prescription drugs & vaccines, subscribe to SSRN’s Pharmaceutical Business & Regulatory Environment eJournal or view other papers here.